Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial

Benzer Materyaller

• Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
  Yazar:: Pulido, F, ve diğerleri
  Baskı/Yayın Bilgisi: (2010)
• The MONET trial: correlation between Hepatitis C coinfection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline
  Yazar:: Arribas, Jose R, ve diğerleri
  Baskı/Yayın Bilgisi: (2010)
• Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV
  Yazar:: Rockstroh, J, ve diğerleri
  Baskı/Yayın Bilgisi: (2010)
• No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial.
  Yazar:: Ajantha Solomon, ve diğerleri
  Baskı/Yayın Bilgisi: (2014-01-01)
• No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET Trial
  Yazar:: Solomon, Ajantha, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)